Q32 Bio

QTTB

Market cap $214M

I initiate Q32 Bio (QTTB) at 'Buy' due to advancing bempikibart for Alopecia Areata and strong upcoming catalysts. Company expects mid-2026 data from both Part B [36-week topline] and Part A OLE of its phase 2a SIGNAL-AA trial. Recent $55M private placement and prior financings extend cash runway into 1H 2028 and beyond, supporting clinical milestones.

WALTHAM, Mass., May 27, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio" or "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has entered into a securities purchase agreement with certain new and existing institutional and accredited investors for the private placement of common stock and pre-funded warrants for an aggregate of approximately $55 million.

The average of price targets set by Wall Street analysts indicates a potential upside of 145.7% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The consensus price target hints at a 163.4% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

-- Bempikibart 36-week topline data readout from Part B of SIGNAL-AA Phase 2a clinical trial on-track for mid-2026 -- -- First patient dosed in SIGNAL-AA Part B open-label extension (OLE) -- -- Completed $10.5 million registered direct offering (RDO) -- -- Cash and cash equivalents of $50.8 million as of March 31, 2026, combined with guaranteed near-term milestone payments from ADX-097 asset sale and proceeds from sales under at-the-market (ATM) program received after the end of the quarter, are expected to provide financial runway into 1H'2028 -- WALTHAM, Mass., May 5, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended March 31, 2026, and provided recent corporate updates.

WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 12:45 p.m.

The consensus price target hints at a 97.7% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Q32 Bio is now largely a single-asset story centered on Bempikibart in alopecia areata, with mid-2026 topline data as the key catalyst. Management sold ADX-097 to Akebia, which brings milestone and royalty payments as an extra while concentrating its efforts on Bempikibart's R&D. Bempikibart's prior data and ongoing OLE data suggest durable responses and possible remission. This keeps my long-term alopecia areata thesis alive for QTTB.

MGY, ESCA, and QTTB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 27, 2026.

DNN, CM, MGY, QTTB and FLXS have been added to the Zacks Rank #1 (Strong Buy) List on March 27, 2026.